The estimated Net Worth of Ventures Fund Iv General Pa... is at least $4.52 Milione dollars as of 13 May 2019. Ventures Pa owns over 500,000 units of Axcella Health Inc stock worth over $4,515,985 and over the last 6 years Ventures sold AXLA stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ventures Pa AXLA stock SEC Form 4 insiders trading
Ventures has made over 1 trades of the Axcella Health Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ventures bought 500,000 units of AXLA stock worth $10,000,000 on 13 May 2019.
The largest trade Ventures's ever made was buying 500,000 units of Axcella Health Inc stock on 13 May 2019 worth over $10,000,000. On average, Ventures trades about 500,000 units every 0 days since 2019. As of 13 May 2019 Ventures still owns at least 986,023 units of Axcella Health Inc stock.
You can see the complete history of Ventures Pa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Axcella Health Inc
Over the last 5 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... e Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
What does Axcella Health Inc do?
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
What does Axcella Health Inc's logo look like?
Complete history of Ventures Pa stock trades at Axcella Health Inc
Axcella Health Inc executives and stock owners
Axcella Health Inc executives and other stock owners filed with the SEC include:
-
Shreeram Aradhye,
Executive Vice President, Chief Development Officer -
Manu Chakravarthy,
Senior Vice President, Chief Medical Officer -
William Hinshaw,
President, Chief Executive Officer, Director -
David Epstein,
Chairman of the Board -
William R. Hinshaw Jr.,
Pres, CEO & Director -
Laurent Chardonnet,
Consultant -
William Baird,
Independent Director -
Catherine Sohn,
Independent Director -
Gary Pisano,
Independent Director -
Gregory Behar,
Independent Director -
Cristina Rondinone,
Independent Director -
Stephen Hoge,
Independent Director -
Stephen Mitchener,
Senior Vice President, Chief Business Officer -
Paul Fehlner,
Senior Vice President, Chief Intellectual Property Officer -
Heidy King-Jones,
Senior Vice President of Legal, General Counsel -
Tony Tramontin,
Senior Vice President of Research and Development , Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer, Senior Vice President -
Karim Azer Ph.D.,
VP of Systems Biology & Discovery -
Dr. Margaret Koziel M.D.,
Sr. VP & Chief Medical Officer -
Dr. Alison D. Schecter M.D.,
Pres of R&D -
Dr. Larry Bell,
Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP -
Virginia R. Dean,
Sr. VP & Chief People Officer -
Dr. Paul Fehlner J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Jason Fredette,
VP of Investor Relations & Corp. Communications -
Health Science Us Holdings,...,
-
Michael Rosenblatt,
Director -
David A Berry,
Director -
Ventures Fund Iv General Pa...,
-
Paul J Sekhri,
Director -
Ventures Fund Iv General Pa...,
-
Des Produits Nestle S.A.Nes...,
-
Alison D. Schecter,
President - Research & Dev. -
Virginia R Dean,
SVP, Chief People Officer -
Margaret Koziel,
Chief Medical Officer -
Ventures Fund Iv General Pa...,
-
Robert Crane,
Chief Financial Officer -
Torben Straight Nissen,
Director -
Robert L. Rosiello,
Director